BeiGene, Ltd. is projected to report Q4 2025 revenue of approximately $1.45 billion and earnings of $1.60 per share, with the stock currently trading at $184.71, significantly below the average analyst price target of $399.75.
Investors are primarily focused on the global sales performance of Brukinsa, the company's blockbuster BTK inhibitor, which has recently surpassed key competitors to become the market leader in new patient starts for chronic lymphocytic leukemia.
This earnings cycle follows the company's strategic rebranding to BeOne Medicines and a critical transition toward sustained GAAP profitability, driven by expanding operating margins and robust commercial execution across the U.S. and Europe. Recent clinical milestones for the Tevimbra franchise and a prolific solid-tumor pipeline continue to serve as major catalysts for long-term growth.